Project Grant R01HL173937
- The National Heart, Lung, and Blood Institute awarded the University of Florida Division of Sponsored Research $228,750 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize pain phenotypes in patients with chronic limb-threatening ischemia, the most advanced form of peripheral arterial disease. The project will systematically document pain features, severity, and mechanisms in lower-extremity CLTI patients to inform precision pain management and...
- The National Institute of Neurological Disorders and Stroke awarded The Ohio State University $10.115 million on September 12, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a prospective observational study modeling diverse experiences and longitudinal trajectories of acute pain in emergency department settings. The study—titled MODEL-PAIN (MOdeling Diverse Experiences and Longitudinal trajectories of pain)—will enroll 2,400 emergency department patients and...
- The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health under the Department of Health and Human Services, awarded the University of Maryland, Baltimore $4.929 million on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate a multi-omic, psychosocial, and environmental model of individual differences in pain and placebo responses. The project investigates chronic pain conditions, particularly...
- The National Institute of Neurological Disorders and Stroke awarded the University of Pittsburgh $9.799 million on September 19, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to elucidate biopsychosocial mechanisms underlying inter-individual differences in movement-evoked pain and functional impairment in knee osteoarthritis. The research uses concurrent ambulatory brain imaging and gait biomechanics during the 6-minute walk test to identify overlapping and distinct...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $1.130557 million on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-viral lipid nanoparticle-delivered gene therapy for acute pain treatment as an alternative to opioids. The project focuses on creating a focal-delivery, non-opioid therapeutic targeting postsurgical pain as the primary indication, with secondary applications to acute exacerbations...
- The National Institute of Neurological Disorders and Stroke awarded a cooperative agreement totaling $7.587 million to the University of Pittsburgh on September 19, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds research to determine the evolution of whole-person pain characteristics in chronic low back pain (CLBP) individuals and to validate, refine, and augment CLBP models by integrating longitudinal data, chronic overlapping pain conditions (COPCs),...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.119 million on September 18, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate computational and clinical tools for understanding pain variability in sickle cell disease. The funded work constitutes a prospective cohort study enrolling 1,250 individuals aged 15 years and older living with sickle cell disease in the United States. Over three years, the research...
- The National Institute of Neurological Disorders and Stroke awarded a cooperative agreement worth $4,041,667 to Cincinnati Children's Hospital Medical Center on September 19, 2025, to conduct research on the biopsychosocial determinants of pediatric-onset chronic musculoskeletal pain. The research employs a mixed retrospective-prospective cohort study design to enroll 600 adolescents and young adults ages 16–26, including 400 with primary chronic musculoskeletal pain or chronic musculoskeletal...
- The National Institute of Neurological Disorders and Stroke awarded the University of Pittsburgh $620,504 on February 11, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate neural circuits that suppress chronic pain signals during competing survival need states. The research focuses on the lateral parabrachial nucleus (LPBN), a brain region that integrates pain information from the spinal cord with competing...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded Mayo Clinic Jacksonville $2,277,111 on September 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop the PAIN (Pain AI Intervention) platform, a wearable sensor-based artificial intelligence system for at-home continuous pain monitoring and personalized opioid management. The project addresses limitations in patient-reported pain scales by deploying validated deep learning algorithms...
The National Institute of Neurological Disorders and Stroke awarded Yale University $4.17 million on August 25, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a biopsychosocial model for peripheral artery disease pain management that integrates vascular interventions with psychological and behavioral assessment. The project develops novel MRI protocols to evaluate blood flow, muscle and nerve microstructure, and metabolism in patients with peripheral artery disease across Rutherford stages 1–6. Over 12 months, the research team will study pain experiences, psychosocial variables, macrovascular information, comorbidities, and opioid usage using two existing multicenter longitudinal registries: the PORTRAIT registry (1,275 patients) and the SCOPE-CLI registry (475 patients). Using Bayesian methods, the team will create pain phenotype clusters and build a precision-medicine foundation for multi-modal pain management that offers safer alternatives to opioids. The work recognizes that ischemic damage alone does not fully explain peripheral artery disease pain; physical, emotional, and behavioral factors play significant roles in chronic pain presentation and treatment response. Performance occurs in Connecticut through November 30, 2030. The project addresses a global disease affecting 230 million people, targeting improved pain management, cardiovascular risk reduction, wound healing, limb preservation, and quality of life for patients experiencing claudication and chronic limb-threatening ischemia.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $4.2m | 8/25/26 |